Cell-Based Medical Technologies

Based in Boston, Massachusetts, HepaLife Technologies Inc., (Symbol: HPLF) is a developer of cell-based medical technologies addressing prevalent human health concerns.

Bioartificial liver device
HepaLife is working towards the first-of-its-kind bioartificial liver device intended for the treatment of liver failure using the Company’s patented PICM-19 liver stem cell line. The HepaLife™ bioartificial liver, currently under development, is designed to serve as a supportive device, either allowing the liver to regenerate upon acute liver failure, or to bridge the patient's liver functions until a transplant is available.

In-vitro toxicology testing platforms
Utilizing its patented liver stem cell line PICM-19, HepaLife is designing testing platforms to improve the pharmaceutical industry’s capability to evaluate drug toxicity and possible side-effects before pharmaceutical compounds are commercially distributed.